Abstract
Heparanase is an endo-beta-D-glucuronidase that degrades heparan sulfate glycosaminoglycan side chains of the proteoglycans in extracellular matrix and basement membrane. Heparanase enzymatic activity is important in the promotion of tumor angiogenesis, primary tumor growth, invasion, and metastasis. Expression of heparanase in many tumor types conversely correlates with prognosis. Much progress has been made in studying the regulation of heparanase expression, processing and activation. The interaction between heparanase and its substrate heparan sulfate has been well characterized. The fact that heparanase was identified as the single predominant heparan sulfate-degrading enzyme in human cancer sparked considerable interest in developing heparanase inhibitors for potential therapeutic applications. Recent progress in drug development led to several classes of heparanase inhibitors, including chemically modified natural products, small molecule inhibitors, and antibodies. Some of these inhibitors have demonstrated potent activities to inhibit tumor angiogenesis, tumor progress, or tumor metastasis. A leading compound, PI-88, is currently being evaluated in clinical phase II trials in patients with melanoma, liver, or lung cancers. This review summarizes the recent progress in heparanase biochemical research and the development of heparanase antagonists as novel anti-cancer therapeutics.
Keywords: tumor growth, metastasis, heparanase, heparan sulfate, extracellular matrix, drug development, Angiogenesis
Current Medicinal Chemistry
Title: Development of Heparanase Inhibitors for Anti-Cancer Therapy
Volume: 13 Issue: 18
Author(s): Zhenping Zhu, Elizabeth Navarro, Paul Kussie, Hu Liu and Hua-Quan Miao
Affiliation:
Keywords: tumor growth, metastasis, heparanase, heparan sulfate, extracellular matrix, drug development, Angiogenesis
Abstract: Heparanase is an endo-beta-D-glucuronidase that degrades heparan sulfate glycosaminoglycan side chains of the proteoglycans in extracellular matrix and basement membrane. Heparanase enzymatic activity is important in the promotion of tumor angiogenesis, primary tumor growth, invasion, and metastasis. Expression of heparanase in many tumor types conversely correlates with prognosis. Much progress has been made in studying the regulation of heparanase expression, processing and activation. The interaction between heparanase and its substrate heparan sulfate has been well characterized. The fact that heparanase was identified as the single predominant heparan sulfate-degrading enzyme in human cancer sparked considerable interest in developing heparanase inhibitors for potential therapeutic applications. Recent progress in drug development led to several classes of heparanase inhibitors, including chemically modified natural products, small molecule inhibitors, and antibodies. Some of these inhibitors have demonstrated potent activities to inhibit tumor angiogenesis, tumor progress, or tumor metastasis. A leading compound, PI-88, is currently being evaluated in clinical phase II trials in patients with melanoma, liver, or lung cancers. This review summarizes the recent progress in heparanase biochemical research and the development of heparanase antagonists as novel anti-cancer therapeutics.
Export Options
About this article
Cite this article as:
Zhu Zhenping, Navarro Elizabeth, Kussie Paul, Liu Hu and Miao Hua-Quan, Development of Heparanase Inhibitors for Anti-Cancer Therapy, Current Medicinal Chemistry 2006; 13 (18) . https://dx.doi.org/10.2174/092986706777935230
DOI https://dx.doi.org/10.2174/092986706777935230 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Evaluation of Gene Expression and In Vitro Enzyme Study for Antiaging Effect of Crocin and Lutein
The Natural Products Journal Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry The De Novo Synthesis of Oligosaccharides: Application to the Medicinal Chemistry SAR-Study of Digitoxin
Current Topics in Medicinal Chemistry The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy VDAC1 Mediated Anticancer Activity of Gallic Acid in Human Lung Adenocarcinoma A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design